|Molecular biomarkers of antidepressant response|
Principal investigator : Gustavo Turecki
Major depression is quite prevalent in the general population and is clearly associated to important consequences in our society. Treatment with antidepressants remains the most common treatment for depressive episodes. In addition, antidepressants are among the most commonly prescribed medications in North America.
This research project will allow us to better understand how individuals suffering from major depression differentiate themselves in terms of their response to antidepressant treatment. As such, the focus will be on two commonly prescribed antidepressants, both of which are already available on the market, in order to compare the molecular markers which differentiate those who respond to antidepressant treatment and those who do not.
- Between 18 and 65 years of age;
- Exhibit certain symptoms of depression: Sadness, hopelessness, loss of interest, feelings of guilt, failure, dissatisfaction, sleep disturbances, changes in appetite, concentration, indecision, fatigue and suicidal ideation.
- Available for 5 interviews and 4 blood draws (genetic screening);
- No illegal drug consumption in the last three months;
- Willingness to receive a known antidepressant treatment, currently on the market, at recommended doses (medication will be provided free of charge for 8 weeks).
To participate in the study, please contact :Iliana Lilova
Phone : 514 761-6131, poste 4468